Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria